Dihydrofolate reductase (DHFR) is an enzyme that plays a crucial role in the metabolism of folate, a type of B vitamin that is essential for DNA synthesis, repair, and overall cell division. Specifically, DHFR catalyzes the reduction of dihydrofolate (DHF) to tetrahydrofolate (THF), a more active form of folate that is used in the production of purines and pyrimidines, which are essential components of DNA and RNA.
Functions of DHFR:
-
Folate Metabolism: DHFR is involved in the folate cycle, which is vital for the production of nucleotides (the building blocks of DNA and RNA). Without DHFR, the conversion of DHF to THF would not occur, leading to impaired DNA synthesis and cellular division.
-
DNA and RNA Synthesis: THF is required for the synthesis of purines (adenine and guanine) and pyrimidines (cytosine, thymine, and uracil), which are necessary for the formation of nucleotides. This makes DHFR essential for rapidly dividing cells, such as those in the bone marrow and intestines.
-
Homocysteine Regulation: THF also plays a role in regulating homocysteine levels in the body. Elevated homocysteine levels can be associated with cardiovascular diseases, so proper functioning of DHFR can help prevent this.
Inhibition of DHFR:
Because DHFR is so critical for cell division and DNA synthesis, it is often targeted in chemotherapy treatments for cancer, as cancer cells tend to divide rapidly and need a constant supply of nucleotides for DNA replication. DHFR inhibitors, like methotrexate, are used in cancer treatment as well as in autoimmune diseases (like rheumatoid arthritis).
-
Methotrexate: This drug acts as a competitive inhibitor of DHFR, blocking the enzyme’s activity and thereby disrupting the folate cycle. As a result, DNA synthesis is impaired, leading to reduced cell division and growth—important for controlling the proliferation of cancer cells or the immune cells in autoimmune conditions.
-
Trimethoprim: Another example of a DHFR inhibitor, this drug is used to treat bacterial infections by inhibiting the bacterial form of DHFR, which is slightly different from the human form, allowing for selective targeting of bacterial cells.
Clinical Relevance:
-
Cancer Treatment: In chemotherapy, methotrexate is commonly used to treat cancers like leukemia, lymphoma, and certain solid tumors by inhibiting DHFR, thus slowing down the division of cancer cells.
-
Autoimmune Diseases: Methotrexate is also a standard treatment for autoimmune diseases like rheumatoid arthritis and psoriasis, where it works to suppress the immune system and reduce inflammation.
-
Folic Acid Deficiency: A deficiency in folate can impair DHFR activity, leading to problems with DNA synthesis, which can result in conditions like megaloblastic anemia. This is often treated with folate supplements or adjustments to diet.
-
Resistance to DHFR Inhibitors: Some cancer cells or bacteria can become resistant to DHFR inhibitors through mutations in the DHFR enzyme, altering its structure and reducing the binding of drugs like methotrexate or trimethoprim.
Structure:
DHFR is a relatively small enzyme that binds to its substrate, dihydrofolate, in the active site. It uses NADPH (nicotinamide adenine dinucleotide phosphate) as a cofactor to reduce dihydrofolate into tetrahydrofolate.
Summary:
<
p class=”” data-start=”3434″ data-end=”3733″>Dihydrofolate reductase is a critical enzyme in folate metabolism, necessary for DNA and RNA synthesis, and is targeted in certain chemotherapy treatments for its role in cell division. Inhibitors of DHFR, like methotrexate and trimethoprim, are widely used in both cancer treatment and antibiotics.